Mathematical model predicts resistance to Herceptin

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 8
Volume 18
Issue 8

Researchers at the University of Edinburgh in Scotland have built a mathematical model to determine the role of PTEN protein expression on resistance to trastuzumab (Herceptin).

Researchers at the University of Edinburgh in Scotland have built a mathematical model to determine the role of PTEN protein expression on resistance to trastuzumab (Herceptin).

Dana Faratian, MD, and colleagues used 56 differential equations to analyze the change in concentrations of 56 separate biological entities including proteins and lipid second messengers.

They worked with 122 breast cancers treated with trastuzumab and found that quantitative PTEN protein expression was a key determinant of who would be resistant or sensitive to trastuzumab. In addition, using the mathematical modeling techniques, the absence of PTEN was more predictive than could be determined using standard multivariate or laboratory analysis (Cancer Res online, July 21, 2009).

The results help explain why some patients still fail on tratuzumab, commented Sofia Merajver, MD, PhD, a Cancer Research editoral board member.

Recent Videos
4 experts in this video
4 experts in this video
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
7 experts are featured in this series.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Yale’s COPPER Center aims to address disparities and out-of-pocket costs for patients, thereby improving the delivery of complex cancer treatment.
7 experts are featured in this series.
7 experts are featured in this series.
A study presented at ASTRO 2025 evaluated the feasibility of using a unified cancer database to consolidate information gathered across 14 institutions.
Related Content